Stock Analysis on Net

Eli Lilly & Co. (NYSE:LLY)

Balance Sheet: Liabilities and Stockholders’ Equity 

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Eli Lilly & Co., consolidated balance sheet: liabilities and stockholders’ equity

US$ in thousands

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Short-term borrowings and current maturities of long-term debt 6,904,500 1,501,100 1,538,300 8,700 1,499,300
Accounts payable 2,598,800 1,930,600 1,670,600 1,606,700 1,405,300
Employee compensation 1,650,400 1,059,800 958,100 997,200 915,500
Sales rebates and discounts 11,689,000 8,784,100 6,845,800 5,853,000 4,933,600
Dividends payable 1,169,200 1,017,200 885,500 770,600 671,500
Other current liabilities 3,281,300 2,845,400 3,154,400 3,245,400 2,350,000
Current liabilities 27,293,200 17,138,200 15,052,700 12,481,600 11,775,200
Long-term debt, excluding current maturities 18,320,800 14,737,500 15,346,400 16,586,600 13,817,900
Accrued retirement benefits 1,438,800 1,305,100 1,954,100 4,094,500 3,698,200
Long-term income taxes payable 3,849,200 3,709,600 3,920,000 3,837,800 3,607,200
Other noncurrent liabilities 2,240,600 1,824,000 3,378,000 3,807,400 3,688,500
Other liabilities 25,849,400 21,576,200 24,598,500 28,326,300 24,811,800
Total liabilities 53,142,600 38,714,400 39,651,200 40,807,900 36,587,000
Common stock, no par value 593,600 594,100 596,300 598,200 598,800
Additional paid-in capital 7,250,400 6,921,400 6,833,400 6,778,500 6,685,300
Retained earnings 10,312,300 10,042,600 8,958,500 7,830,200 4,920,400
Employee benefit trust (3,013,200) (3,013,200) (3,013,200) (3,013,200) (3,013,200)
Accumulated other comprehensive loss (4,327,000) (3,844,600) (4,343,100) (6,496,400) (6,523,600)
Cost of common stock in treasury (44,200) (50,500) (52,700) (55,700) (60,800)
Total Eli Lilly and Company shareholders’ equity 10,771,900 10,649,800 8,979,200 5,641,600 2,606,900
Noncontrolling interests 91,800 125,600 175,600 183,600 92,200
Total equity 10,863,700 10,775,400 9,154,800 5,825,200 2,699,100
Total liabilities and equity 64,006,300 49,489,800 48,806,000 46,633,100 39,286,100

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Eli Lilly & Co. current liabilities increased from 2021 to 2022 and from 2022 to 2023.
Other liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Eli Lilly & Co. other liabilities decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Eli Lilly & Co. total liabilities decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level.
Total Eli Lilly and Company shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Eli Lilly & Co. total Eli Lilly and Company shareholders’ equity increased from 2021 to 2022 and from 2022 to 2023.